At the American Diabetes Association’s 78th Scientific Sessions, researchers presented ways in which education—for both patients and providers—can help improve the care of patients with diabetes who use biosimilar or follow-on insulins.
At the American Diabetes Association’s 78th Scientific Sessions, held from June 22 to 26 in Orlando, Florida, researchers presented ways in which education—for both patients and providers—can help improve the care of patients with diabetes who use biosimilar or follow-on insulins.
Educational Program Benefits Patients Initiating Biosimilar Insulin
Researchers from Bangalore, India, presented on a structured patient education program—the Insulin Therapy Assistance Program—developed by biosimilar maker Biocon (which funded the research) for patients with type 2 diabetes (T2D) who receive biosimilar insulin therapy with either human insulin or basal insulin.1
A total of 10,426 patients with T2D enrolled in the patient program, and received training on diabetes, lifestyle management, diet, exercise, and general healthcare issues from trained and certified healthcare providers. These patients were observed at 3, 6, and 9 months after beginning the program and initiating their biosimilar insulin therapy.
Mean blood glucose was significantly reduced from a baseline level of 183.78 (standard deviation [SD], 54.74) to 145.15 (SD, 33.79) at month 3, and further reduced to 132.80 (SD, 29.38) and 133.98 (SD, 25.13) at months 6 and 9, respectively. Glycated hemoglobin fell from 10.10% (SD, 1.75%) at baseline to 7.85% (SD, 1.06%) at the end of month 9.
Not only was the biosimilar insulin used in the program safe and well tolerated among the enrolled patients, concluded the authors, but the patient education program helped produce significant improvement in patients’ glycemic parameters.
Continuing Medical Education Improves Provider Competence With Follow-on Insulin
American researchers also reported on the benefits of educational programs, this time with a focus on healthcare providers. The research team sought to assess how an online, video-based, continuing medical education (CME) roundtable activity could improve clinical knowledge and competence among primary care physicians (PCPs) and specialists in diabetes and endocrinology with respect to follow-on basal insulin use (in the United States, subsequent-entry insulins are not currently regulated as biosimilars but instead as follow-on biologic products).2
In the online activity, which launched in February 2017, PCPs (n = 284) demonstrated a lower baseline knowledge of follow-on basal insulin than did specialists (n = 57); only 9% of PCPs, versus 23% of specialists, correctly identified pharmacokinetic and pharmacodynamic data for follow-on insulin glargine. Similarly, only 14% of PCPs, versus 30% of specialists, correctly identified a patient for whom a follow-on basal insulin would be a good therapeutic option.
After completing the activity, both PCPs and specialists demonstrated improvements in their knowledge, with 56% more PCPs and 38% more specialists accurately identifying patients who would be appropriate candidates for follow-on basal insulin use. In addition, 30% more PCPs and 16% more specialists correctly identified PK and PD data for follow-on insulin glargine post-activity.
Notably, after the activity, 61% of PCPs and 37% of specialists reported that they had increased confidence in switching patients with T2D to follow-on insulin glargine.
The authors state that their study demonstrates the success of such CME activities on improving clinical knowledge and competence with follow-on insulin products among healthcare providers.
References
1. Jabeen S, Pawar D, Vs S, Raj P. Impact of Insulin Therapy Assistance Program, a Patient Support Program, on 10,426 Indian T2DM patients to assess safety and efficacy with biosimilar insulin. Presented at The American Diabetes Association 78th Scientific Sessions, June 22-26, 2018; Orlando, Florida. Poster 1059-P. ada.apprisor.org/epsAbstractADA.cfm?id=1.
2. Larkin A, Dropkin J, Le A. Follow-on basal insulin—can online CME improve clinical knowledge and ability to use effectively? Presented at The American Diabetes Association 78th Scientific Sessions, June 22-26, 2018; Orlando, Florida. Poster 1005-P. ada.apprisor.org/epsAbstractADA.cfm?id=1.
Physician and Patient Perspectives After Starting or Switching to Amgevita in IBD
March 23rd 2024A real-world study surveying physicians and patients on adalimumab biosimilar ABP 501 (Amgevita) in inflammatory bowel disease (IBD) found both patients initiating ABP 501 and those who had switched from the reference product had higher satisfaction levels.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
The Role of Biosimilars: Advancing Access, Financial Health, and System Sustainability
March 11th 2024Kashyap Patel, MD, CEO of Carolina Blood and Cancer Care, a member of the Community Oncology Alliance, and member of The Center for Biosimilars® Advisory Board, glances back at the development of the biosimilar industry and the last 5 years of progress.
Pipelines and Preparation: How the US Can Prepare for More RA Biosimilars
April 16th 2023What can practices do to prepare for all the biosimilars to treat rheumatoid arthritis (RA) coming down the pipeline? And how can they ensure that the lower-than-anticipated adoption rates for infliximab biosimilars are not repeated? Robert Zutaut, RPh, from McKesson Provider Solutions, tackles all this and more on this episode of Not So Different.
Cardinal Health Report Showcases Biosimilar Growth, Provider and Payer Evolution, and More
February 29th 2024In its annual biosimilars report, Cardinal Health provided updates on how provider acceptance growth, evolving payer dynamics, and the growing pipeline for biosimilars will shape the biosimilar landscape over the next 5 years.
Biosimilar Substitution Within OCM Could Result in Lower Total Cost of Care
February 16th 2024Researchers found that the total cost of care per oncology episode was significantly lowered when biosimilar substitution was implemented in Medicare’s Oncology Care Model (OCM), suggesting that biosimilar uptake can serve as a critical tool to mitigate risk and improve financial performance for providers.